Literature DB >> 28187285

Transcriptional Addiction in Cancer.

James E Bradner1, Denes Hnisz2, Richard A Young3.   

Abstract

Cancer arises from genetic alterations that invariably lead to dysregulated transcriptional programs. These dysregulated programs can cause cancer cells to become highly dependent on certain regulators of gene expression. Here, we discuss how transcriptional control is disrupted by genetic alterations in cancer cells, why transcriptional dependencies can develop as a consequence of dysregulated programs, and how these dependencies provide opportunities for novel therapeutic interventions in cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28187285      PMCID： PMC5308559          DOI： 10.1016/j.cell.2016.12.013

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  139 in total

Review 1.  A blueprint for engineering cell fate: current technologies to reprogram cell identity.

Authors:  Samantha A Morris; George Q Daley
Journal:  Cell Res       Date:  2013-01-01       Impact factor: 25.617

2.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Authors:  Camilla L Christensen; Nicholas Kwiatkowski; Brian J Abraham; Julian Carretero; Fatima Al-Shahrour; Tinghu Zhang; Edmond Chipumuro; Grit S Herter-Sprie; Esra A Akbay; Abigail Altabef; Jianming Zhang; Takeshi Shimamura; Marzia Capelletti; Jakob B Reibel; Jillian D Cavanaugh; Peng Gao; Yan Liu; Signe R Michaelsen; Hans S Poulsen; Amir R Aref; David A Barbie; James E Bradner; Rani E George; Nathanael S Gray; Richard A Young; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

Review 4.  Linking somatic genetic alterations in cancer to therapeutics.

Authors:  Darrin Stuart; William R Sellers
Journal:  Curr Opin Cell Biol       Date:  2009-03-26       Impact factor: 8.382

5.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

Review 6.  Looping back to leap forward: transcription enters a new era.

Authors:  Michael Levine; Claudia Cattoglio; Robert Tjian
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

7.  Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Maurizio Affer; Marta Chesi; Wei-Dong G Chen; Jonathan J Keats; Yulia N Demchenko; Anna V Roschke; Scott Van Wier; Rafael Fonseca
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

8.  Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Authors:  Shaokun Shu; Charles Y Lin; Housheng Hansen He; Robert M Witwicki; Doris P Tabassum; Justin M Roberts; Michalina Janiszewska; Sung Jin Huh; Yi Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G Stover; Muhammad B Ekram; Jonathan Brown; Clive D'Santos; Ian E Krop; Deborah Dillon; Michael McKeown; Christopher Ott; Jun Qi; Min Ni; Prakash K Rao; Melissa Duarte; Shwu-Yuan Wu; Cheng-Ming Chiang; Lars Anders; Richard A Young; Eric Winer; Antony Letai; William T Barry; Jason S Carroll; Henry Long; Myles Brown; X Shirley Liu; Clifford A Meyer; James E Bradner; Kornelia Polyak
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

9.  ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas.

Authors:  Hanseul Yang; Daniel Schramek; Rene C Adam; Brice E Keyes; Ping Wang; Deyou Zheng; Elaine Fuchs
Journal:  Elife       Date:  2015-11-21       Impact factor: 8.140

10.  An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.

Authors:  Yotam Drier; Matthew J Cotton; Kaylyn E Williamson; Shawn M Gillespie; Russell J H Ryan; Michael J Kluk; Christopher D Carey; Scott J Rodig; Lynette M Sholl; Amir H Afrogheh; William C Faquin; Lurdes Queimado; Jun Qi; Michael J Wick; Adel K El-Naggar; James E Bradner; Christopher A Moskaluk; Jon C Aster; Birgit Knoechel; Bradley E Bernstein
Journal:  Nat Genet       Date:  2016-02-01       Impact factor: 38.330
View more
  347 in total

Review 1.  BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.

Authors:  Patricia Cristine Borck; Lian-Wang Guo; Jorge Plutzky
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 2.  Super-Enhancer-Driven Transcriptional Dependencies in Cancer.

Authors:  Satyaki Sengupta; Rani E George
Journal:  Trends Cancer       Date:  2017-04-12

3.  A Caenorhabditis elegans protein with a PRDM9-like SET domain localizes to chromatin-associated foci and promotes spermatocyte gene expression, sperm production and fertility.

Authors:  Christoph G Engert; Rita Droste; Alexander van Oudenaarden; H Robert Horvitz
Journal:  PLoS Genet       Date:  2018-04-27       Impact factor: 5.917

4.  ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.

Authors:  Yan Chen; Bo Zhang; Lei Bao; Lai Jin; Mingming Yang; Yan Peng; Ashwani Kumar; Jennifer E Wang; Chenliang Wang; Xuan Zou; Chao Xing; Yingfei Wang; Weibo Luo
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

5.  Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Authors:  Dyana T Saenz; Warren Fiskus; Taghi Manshouri; Christopher P Mill; Yimin Qian; Kanak Raina; Kimal Rajapakshe; Cristian Coarfa; Raffaella Soldi; Prithviraj Bose; Gautam Borthakur; Tapan M Kadia; Joseph D Khoury; Lucia Masarova; Agnieszka J Nowak; Baohua Sun; David N Saenz; Steven M Kornblau; Steve Horrigan; Sunil Sharma; Peng Qiu; Craig M Crews; Srdan Verstovsek; Kapil N Bhalla
Journal:  Leukemia       Date:  2018-12-21       Impact factor: 11.528

6.  Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.

Authors:  Weiwei Shan; Jiao Yuan; Zhongyi Hu; Junjie Jiang; Yueying Wang; Nicki Loo; Lingling Fan; Zhaoqing Tang; Tianli Zhang; Mu Xu; Yutian Pan; Jiaqi Lu; Meixiao Long; Janos L Tanyi; Kathleen T Montone; Yi Fan; Xiaowen Hu; Youyou Zhang; Lin Zhang
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

Review 7.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

Review 8.  Super-enhancer function and its application in cancer targeted therapy.

Authors:  Faqing Tang; Zongbei Yang; Yuan Tan; Yuejin Li
Journal:  NPJ Precis Oncol       Date:  2020-02-12

Review 9.  Molecular mechanisms driving transcriptional stress responses.

Authors:  Anniina Vihervaara; Fabiana M Duarte; John T Lis
Journal:  Nat Rev Genet       Date:  2018-06       Impact factor: 53.242

10.  Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.

Authors:  Dyana T Saenz; Warren Fiskus; Christopher P Mill; Dimuthu Perera; Taghi Manshouri; Bernardo H Lara; Vrajesh Karkhanis; Sunil Sharma; Stephen K Horrigan; Prithviraj Bose; Tapan M Kadia; Lucia Masarova; Courtney D DiNardo; Gautam Borthakur; Joseph D Khoury; Koichi Takahashi; Srividya Bhaskara; Charles Y Lin; Michael R Green; Cristian Coarfa; Craig M Crews; Srdan Verstovsek; Kapil N Bhalla
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.